Anti-Her2 Antibody-Drug Conjugate A166
Tumor Of Salivary Gland
Klus Pharma Inc.antibody_drug_conjugatePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Tumor Of Salivary Gland cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trastuzumab Cancer Research UK | Phase 2/3 | B |
Pertuzumab Cancer Research UK | Phase 2/3 | B |
Alectinib Hoffmann-La Roche | Phase 2 | CCC |
Ava-6000 (Fap-Activated Doxorubicin Prodrug) Avacta Life Sciences Ltd | Phase 1 | CC |
Rimiducid Poseida Therapeutics, Inc. | Phase 1 | CC |
P-Psma-101 Car-T Cells Poseida Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
Anti-Her2 Antibody-Drug Conjugate A166 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →